<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-05-23T07:01:36.446Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Dermatol</journal-id><journal-id journal-id-type="publisher-id">ced</journal-id><journal-title-group><journal-title>Clinical and Experimental Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0307-6938</issn><issn pub-type="epub">1365-2230</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39847610</article-id><article-id pub-id-type="pmc">PMC12099064</article-id>
<article-id pub-id-type="doi">10.1093/ced/llaf005</article-id><article-id pub-id-type="publisher-id">llaf005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject><subject>AcademicSubjects/MED00160</subject><subject>AcademicSubjects/MED00240</subject></subj-group></article-categories><title-group><article-title>Novel microsatellite instability test of sebaceous tumours to facilitate low-cost universal screening for Lynch syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5395-0099</contrib-id><name><surname>Gallon</surname><given-names>Richard</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="supporting">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="lead">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="lead">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="lead">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization" degree-contribution="equal">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="lead">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &#x00026; editing</role><aff>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff><xref rid="FM1" ref-type="author-notes"/><xref rid="llaf005-cor1" ref-type="corresp"/><xref rid="FN01" ref-type="author-notes"/><!--richard.gallon@newcastle.ac.uk--></contrib><contrib contrib-type="author"><name><surname>Holt</surname><given-names>Georgie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="supporting">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Alfailakawi</surname><given-names>Waleed</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="supporting">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Husain</surname><given-names>Akhtar</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="supporting">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="equal">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Department of Pathology, Royal Victoria Infirmary</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Claire</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="equal">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Department of Pathology, Royal Victoria Infirmary</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Sowter</surname><given-names>Peter</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="supporting">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Santibanez-Koref</surname><given-names>Mauro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="supporting">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Biosciences Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Michael S</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Biosciences Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Burn</surname><given-names>John</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="supporting">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Sam</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="supporting">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization" degree-contribution="equal">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &#x00026; editing</role><aff>
<institution>Department of Pathology, Royal Victoria Infirmary</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5850-5680</contrib-id><name><surname>Rajan</surname><given-names>Neil</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="lead">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="supporting">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization" degree-contribution="supporting">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &#x00026; editing</role><aff>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff><aff>
<institution>Department of Dermatology, Royal Victoria Infirmary</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country country="GB">UK</country></aff></contrib></contrib-group><author-notes><corresp id="llaf005-cor1">Correspondence: Richard Gallon. Email: <email>richard.gallon@newcastle.ac.uk</email></corresp><fn id="FM1"><p>R.G., G.H. and W.A. contributed equally.</p></fn><fn id="FN01" fn-type="COI-statement"><p>Conflicts of interest: R.G., M. S-K., M.S.J. and J.B. are named inventors on patents covering the microsatellite instability markers analysed: WO/2018/037231 (published 1 March 2018), WO/2021/019197 (published 4 February 2021) and GB2114136.1 (filed 1 October 2021). The other authors declare no conflicts of interest.</p></fn></author-notes><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-01-23"><day>23</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>1</month><year>2025</year></pub-date><volume>50</volume><issue>6</issue><fpage>1155</fpage><lpage>1162</lpage><history><date date-type="received"><day>08</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2024</year></date><date date-type="corrected-typeset"><day>27</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="llaf005.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>One in five patients with sebaceous tumours (STs) may have Lynch syndrome (LS), an inherited disorder that increases the risk of developing cancer. Patients with LS benefit from cancer surveillance and prevention programmes and immunotherapy. While universal tumour mismatch repair (MMR) deficiency testing is recommended in colorectal and endometrial cancers to screen for LS, there is no consensus screening strategy for STs, leading to low testing rates and inequity of care.</p></sec><sec id="s2"><title>Objectives</title><p>To assess a low-cost and scalable sequencing-based microsatellite instability (MSI) assay, previously shown to enhance LS screening of colorectal cancers, for MMR deficiency detection in STs against the current clinical standard of immunohistochemistry (IHC).</p></sec><sec id="s3"><title>Methods</title><p>Consecutive ST cases (<italic toggle="yes">n</italic> = 107) were identified from the records of a single pathology department. MMR protein IHC staining was interpreted by a consultant histopathologist. MSI analysis used amplicon sequencing of 14 microsatellites and a naive Bayesian classifier to calculate the sample MSI score.</p></sec><sec id="s4"><title>Results</title><p>Loss of MMR protein expression was observed in 49/104 STs with interpretable IHC [47.1%, 95% confidence interval (CI) 37.3&#x02013;57.2]. MMR deficiency was less frequent in carcinoma than in adenoma and sebaceoma (<italic toggle="yes">P</italic> = 4.74 &#x000d7; 10<sup>&#x02013;3</sup>). The majority of MMR-deficient STs had concurrent loss of MSH2 and MSH6 expression. The MSI score achieved a receiver operator characteristic area under curve of 0.944 relative to IHC. Lower MSI scores were associated with MSH6 deficiency.</p></sec><sec id="s5"><title>Conclusions</title><p>These data support MSI testing as an adjunct or alternative to MMR IHC in STs. Integration of STs into established LS screening pathways using this high-throughput methodology could increase testing and reduce costs.</p></sec></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="ga1"><label>Graphical Abstract</label><graphic xlink:href="llaf005_ga" position="float"/></fig>
</p></abstract><abstract abstract-type="teaser"><p>Lynch syndrome (LS) screening using reflex tumour mismatch repair (MMR) deficiency testing is recommended in all colorectal and endometrial cancers but not in sebaceous tumours (STs) despite LS being more common among patients with STs. A novel MMR deficiency test for STs, the Newcastle MSI-Plus assay, demonstrated equivalent diagnostic accuracy to the clinical standard immunohistochemistry (IHC) test. The MSI-Plus assay is in clinical service in northern England for colorectal cancers and is cheaper and more scalable than IHC. Integration of ST testing with these established screening pathways could streamline service provision, reduce testing inequity, make healthcare cost savings and, ultimately, increase LS diagnoses.</p></abstract><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>National Institute for Health and Care Research</institution><institution-id institution-id-type="DOI">10.13039/501100000272</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Biomedical Research Centre</institution><institution-id institution-id-type="DOI">10.13039/501100018942</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>North Eastern Skin Research Fund</institution></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Cancer Research UK</institution><institution-id institution-id-type="DOI">10.13039/501100000289</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Kuwait Ministry of Health</institution></institution-wrap>
</funding-source></award-group></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><boxed-text id="llaf005-box1" position="anchor"><caption><title>What is already known about this topic?</title></caption><list list-type="bullet"><list-item><p>Tumour mismatch repair (MMR) deficiency testing can be used to screen for Lynch syndrome (LS), an inherited disorder that increases the risk of developing cancer.</p></list-item><list-item><p>Universal testing for LS is recommended for colorectal and endometrial cancers but not for sebaceous tumours (STs), despite LS being sixfold more prevalent among patients with STs.</p></list-item><list-item><p>Only 34% of sebaceous carcinomas were tested for LS in England in 2018, highlighting a disparity in LS screening between visceral and cutaneous malignancies.</p></list-item></list></boxed-text><boxed-text id="llaf005-box2" position="anchor"><caption><title>What does this study add?</title></caption><list list-type="bullet"><list-item><p>We assessed a novel, low-cost and scalable MMR deficiency test for sebaceous tumours, the Newcastle MSI-Plus assay.</p></list-item><list-item><p>The MSI-Plus assay demonstrated equivalence as an MMR deficiency test compared with immunohistochemistry, the clinical standard.</p></list-item><list-item><p>MSH6-deficient tumours had lower microsatellite instability, consistent with other tumour types.</p></list-item><list-item><p>STs could be integrated with established LS screening pathways already using the MSI-Plus assay to streamline service provision, increase testing and reduce costs.</p></list-item></list></boxed-text><p>Sebaceous tumours (STs) are a rare group of skin tumours of the sebaceous gland, encompassing sebaceoma, adenoma and carcinoma.<sup><xref rid="llaf005-B1" ref-type="bibr">1</xref></sup> STs are strongly associated with the cancer predisposition syndrome, Lynch syndrome (LS), with up to one in five patients with STs having LS.<sup><xref rid="llaf005-B2" ref-type="bibr">2</xref></sup> Screening of STs for LS is not routinely performed in every case, and variation in practice has been highlighted, suggesting inequity of care.<sup><xref rid="llaf005-B3" ref-type="bibr">3</xref></sup> Notably, reflex mismatch repair (MMR) deficiency testing of all colorectal cancers (CRCs) and all endometrial cancers (ECs) to screen for LS is recommended as a more sensitive and more cost-effective approach than using clinical criteria.<sup><xref rid="llaf005-B4" ref-type="bibr">4&#x02013;7</xref></sup> A recent meta-analysis found that &#x0003e; 95% of all types of STs from patients with LS (<italic toggle="yes">n</italic> = 177) were MMR deficient,<sup><xref rid="llaf005-B8" ref-type="bibr">8</xref></sup> suggesting MMR deficiency testing of STs may have a higher sensitivity for LS screening than the 80&#x02013;85% previously reported on which current screening guidelines that use clinical criteria are based.<sup><xref rid="llaf005-B9" ref-type="bibr">9&#x02013;11</xref></sup> These observations, together with the potential benefit from integration with established pipelines for CRC and EC, suggest reflex MMR deficiency testing of STs could improve LS detection, as has recently been called for by an expert and patient group in the UK.<sup><xref rid="llaf005-B12" ref-type="bibr">12</xref></sup></p><p>LS (OMIM #609310, #120435, #614350 and #614337) is diagnosed in individuals carrying a constitutional (germline) pathogenic variant affecting one of four genes (<italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic>) that constitute the core MMR system. It is associated with gastrointestinal and genitourinary tract cancers, as well as STs and other rare tumour types.<sup><xref rid="llaf005-B4" ref-type="bibr">4</xref>,<xref rid="llaf005-B5" ref-type="bibr">5</xref></sup> MMR deficiency is characteristic of LS tumours and, hence, is a useful biomarker in LS screening. Once identified, patients with LS benefit from personalized healthcare and cancer risk management, including immune checkpoint inhibitor therapy, genetic counselling, surveillance, prophylactic surgery and daily acetylsalicylic acid (aspirin) intake.<sup><xref rid="llaf005-B4" ref-type="bibr">4</xref>,<xref rid="llaf005-B5" ref-type="bibr">5</xref>,<xref rid="llaf005-B13" ref-type="bibr">13</xref>,<xref rid="llaf005-B14" ref-type="bibr">14</xref></sup></p><p>Immunohistochemistry (IHC) is the clinical standard used for MMR deficiency testing of STs. Microsatellite instability (MSI) analysis, the detection of insertion&#x02013;deletion mutations in repetitive microsatellite DNA sequences, is an alternative assay for MMR deficiency but is rarely used in ST.<sup><xref rid="llaf005-B3" ref-type="bibr">3</xref></sup> IHC and newer next-generation sequencing (NGS)-based MSI assays have not been compared in unselected cases of ST at scale. MSI assays have the advantage of offering a functional readout of MMR status to avoid false-negative results due to missense (and other) MMR variants that disrupt function but not expression,<sup><xref rid="llaf005-B15" ref-type="bibr">15</xref>,<xref rid="llaf005-B16" ref-type="bibr">16</xref></sup> while NGS offers scalable and automatable protocols and analysis to reduce the burden of testing on pathologists&#x02019; and scientists&#x02019; time. The Newcastle MSI-Plus assay, a novel amplicon-sequencing MSI and mutation hotspot assay, has recently been deployed in National Health Service (NHS) diagnostic laboratories in the north of England for CRC testing. In its first year, it tested &#x0003e; 95% of the approximately 2500 CRC diagnoses, halved testing turnaround times and doubled detection of patients at risk of LS compared with previous years.<sup><xref rid="llaf005-B17" ref-type="bibr">17</xref></sup> Because of its low cost and scalability, the assay has the capacity to cover additional tumour types such as ST. Therefore, we investigated the sensitivity and specificity of the Newcastle MSI-Plus assay in ST compared with IHC, with a view to harmonizing LS screening of patients with ST across established clinical pathways.</p><sec sec-type="materials|methods" id="llaf005-s1"><title>Materials and methods</title><sec id="llaf005-s1.1"><title>Samples</title><p>Patients with STs diagnosed between November 2012 and March 2021 with available formalin-fixed paraffin-&#x000ad;embedded (FFPE) tissue were identified through the NovoPath Cellular Pathology Research Department of the Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust (Table <xref rid="sup1" ref-type="supplementary-material">S1</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supporting Information</xref>). STs were classified as sebaceoma, adenoma or carcinoma by a consultant histopathologist using haematoxylin and eosin-stained tissue sections and World Health Organization classification criteria.<sup><xref rid="llaf005-B18" ref-type="bibr">18</xref></sup></p></sec><sec id="llaf005-s1.2"><title>Haematoxylin and eosin staining and mismatch repair protein immunohistochemistry</title><p>Haematoxylin and eosin staining and MMR protein IHC of FFPE tissue sections were performed by NovoPath using the Dako CoverStainer (Agilent Technologies, Santa Clara, CA, USA) and Ventana Discovery Ultra automated IHC staining platform (Ventana Medical Systems, Basel, Switzerland), respectively. Detailed protocols are provided in Appendix <xref rid="sup1" ref-type="supplementary-material">S1</xref> (see <xref rid="sup1" ref-type="supplementary-material">Supporting Information</xref>). Stained sections were viewed using a Leica DM2000 microscope (Leica Microsystems, Milton Keynes, UK). MMR protein IHC was interpreted by a consultant histopathologist. Images were captured with a Nikon DS-Fi1-U2 (Nikon Instruments, Melville, NY, USA) at &#x000d7; 400 magnification.</p></sec><sec id="llaf005-s1.3"><title>DNA extraction</title><p>Genomic DNA was extracted from 10-&#x003bc;m tissue curls using the Qiagen GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany). DNA concentrations were quantified using a QuBit 3 Fluorometer (Invitrogen, Waltham, MA, USA).</p></sec><sec id="llaf005-s1.4"><title>Newcastle MSI-Plus assay</title><p>The Newcastle MSI-Plus assay followed the standard protocols for clinical diagnostic testing of CRCs in the Northern Genetics Service, The Newcastle upon Tyne Hospitals NHS Foundation Trust.<sup><xref rid="llaf005-B17" ref-type="bibr">17</xref></sup> In brief, 14 tissue agnostic, highly sensitive MSI markers<sup><xref rid="llaf005-B19" ref-type="bibr">19</xref>,<xref rid="llaf005-B20" ref-type="bibr">20</xref></sup> were amplified and tagged with Illumina sequencing adapters, sample indexes and custom sequencing primer binding sites (Illumina, San Diego, CA, USA) using multiplex polymerase chain reaction. Amplicons were sequenced to approximately &#x000d7; 2000 read depth on a MiSeq (Illumina). Reads were aligned to the human reference genome hg19 using BWA version 0.7.17 mem<sup><xref rid="llaf005-B21" ref-type="bibr">21</xref></sup> and microsatellite allele frequencies extracted using R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria), as previously described.<sup><xref rid="llaf005-B19" ref-type="bibr">19</xref></sup> An MSI score was calculated for each sample using a Bayesian classification method, based on the frequency and allelic bias of microsatellite deletions,<sup><xref rid="llaf005-B19" ref-type="bibr">19</xref></sup> trained on data from a published CRC cohort.<sup><xref rid="llaf005-B17" ref-type="bibr">17</xref></sup> An MSI score &#x0003e; 0 indicates a sample is MSI-high (MSI-H; MMR deficient). An MSI score &#x0003c; 0 indicates a sample is microsatellite stable (MSS; MMR proficient). An MSI score passed quality control with a median MSI marker read depth &#x02265; 100, and scores between &#x02013;5 and +5 required a repeat assay to confirm the classification, according to clinically established criteria.<sup><xref rid="llaf005-B17" ref-type="bibr">17</xref></sup></p></sec><sec id="llaf005-s1.5"><title>Mismatch repair gene sequencing and variant detection</title><p>MMR genes were sequenced using molecular inversion probe (MIP) amplicon sequencing.<sup><xref rid="llaf005-B22" ref-type="bibr">22</xref></sup> In total, 214 MIPs capturing <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic> exons (Table <xref rid="sup1" ref-type="supplementary-material">S2</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supporting Information</xref>) were designed using MIPgen.<sup><xref rid="llaf005-B23" ref-type="bibr">23</xref></sup> MIPs (synthesized by Metabion, Planegg, Germany) were pooled, 5&#x002b9;-phosphorylated using T4 Polynucleotide Kinase (New England Biolabs, Ipswich, MA, USA), and diluted to 0.1&#x02005;nmol L<sup>&#x02013;1</sup> each as previously described.<sup><xref rid="llaf005-B24" ref-type="bibr">24</xref></sup> MIP amplification of sample DNAs, library generation and sequencing to approximately &#x000d7; 1500 read depth followed published protocols.<sup><xref rid="llaf005-B24" ref-type="bibr">24</xref></sup> Reads were aligned to the human reference genome hg19 using BWA version 0.7.17 mem.<sup><xref rid="llaf005-B21" ref-type="bibr">21</xref></sup> Binary alignment and map (BAM) files were generated using SAMtools version 1.9.<sup><xref rid="llaf005-B25" ref-type="bibr">25</xref></sup> BAMclipper removed the MIP targeting arm sequence from reads.<sup><xref rid="llaf005-B26" ref-type="bibr">26</xref></sup> Variants were called using two variant callers from GATK version 4.6.0.0,<sup><xref rid="llaf005-B27" ref-type="bibr">27</xref></sup> to maximize variant detection, HaplotypeCaller and Mutect2, with &#x02018;&#x02013;max-reads-per-alignment-start&#x02019; set to 0 and &#x02018;&#x02013;dont-use-soft-clipped-bases&#x02019; set to true. Variants were annotated using Ensembl Variant Effect Predictor version 102.0,<sup><xref rid="llaf005-B28" ref-type="bibr">28</xref></sup> including SIFT and PolyPhen prediction of missense variant pathogenicity. Variants were filtered using R version 4.2.2, the vcfR package<sup><xref rid="llaf005-B29" ref-type="bibr">29</xref></sup> and custom thresholds (Appendix <xref rid="sup1" ref-type="supplementary-material">S1</xref>), and checked in ClinVar.<sup><xref rid="llaf005-B30" ref-type="bibr">30</xref></sup></p></sec><sec id="llaf005-s1.6"><title>Data analysis and statistics</title><p>Analyses used R version 4.2.2 and packages &#x02018;ggplot2&#x02019;<sup><xref rid="llaf005-B31" ref-type="bibr">31</xref></sup> and &#x02018;pROC&#x02019;.<sup><xref rid="llaf005-B32" ref-type="bibr">32</xref></sup> Frequencies and sensitivity and specificity estimates were given as 95% confidence intervals (CI) based on a Clopper&#x02013;Pearson binomial distribution. A Fisher&#x02019;s exact test was used to assess associations in counts across two categorical variables. A Mann&#x02013;Whitney <italic toggle="yes">U</italic>-test or Kruskal&#x02013;Wallis test was used to assess associations between a continuous variable and categorical variable of two or more groups, respectively. Receiver operator characteristic area under the curve (ROCauc) was calculated using the &#x02018;pROC roc()&#x02019; function. All statistical tests were two-sided.</p></sec></sec><sec sec-type="results" id="llaf005-s2"><title>Results</title><sec id="llaf005-s2.1"><title>Description of cohort of patients with sebaceous tumours</title><p>In total, 110 consecutive STs from distinct patients (Table <xref rid="sup1" ref-type="supplementary-material">S1</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supporting Information</xref>), diagnosed between November 2012 and March 2021, were available for MSI testing and MMR protein IHC. Histological review identified 33 sebaceoma, 61 adenoma and 13 carcinoma. Three samples were found to have an ambiguous, likely nonsebaceous, tissue of origin or to not contain any tumour cells, and were excluded. Of the 107 patients with histologically confirmed ST, 64 were men and 43 were women. The median age at diagnosis was 77&#x02005;years (range 29&#x02013;97). There was no association between tumour type and patient age (<italic toggle="yes">P</italic> = 0.10) or sex (<italic toggle="yes">P</italic> = 0.26).</p></sec><sec id="llaf005-s2.2"><title>Almost half of sebaceous tumours show loss of mismatch repair protein expression</title><p>Each ST was analysed by IHC of all four MMR proteins to provide a reference result against which the sensitivity and specificity of MSI analysis could be determined. Three samples, one sebaceoma and two adenomas, failed to give interpretable IHC staining because of issues with sample processing. Of the 104 STs with interpretable IHC, 52 (50.0%, 95% CI 40.0&#x02013;60.0) retained MMR protein expression, observed as uniform nuclear expression with slight variation dependent on cell proliferative activity. Forty-nine STs (47.1%, 95% CI 37.3&#x02013;57.2) showed a clear loss of expression of at least one MMR protein, observed as complete negative staining in tumour cells in most cases, but also very weak or very focal staining. The three remaining STs (2.9%, 95% CI 0.6&#x02013;8.2), all of which were carcinoma, had equivocal staining in one or more MMR proteins leading to uncertain MMR status. There was no association between IHC classification and patient age (<italic toggle="yes">P</italic> = 0.26) or sex (<italic toggle="yes">P</italic> &#x0003e; 0.99). Unequivocal MMR expression loss was associated with tumour type (<italic toggle="yes">P</italic> = 4.74 &#x000d7; 10<sup>&#x02013;3</sup>), with more frequent loss among sebaceoma (<italic toggle="yes">n</italic> = 14/32; 44%, 95% CI 26&#x02013;62) and adenoma (<italic toggle="yes">n</italic> = 32/59; 54%, 95% CI 41&#x02013;67) than carcinoma (<italic toggle="yes">n</italic> = 3/13; 23%, 95% CI 5&#x02013;54] (Table <xref rid="llaf005-T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="llaf005-T1"><label>Table 1</label><caption><p>Mismatch repair protein immunohistochemistry (IHC) classification compared with sebaceous tumour type</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">IHC classification</th><th align="center" colspan="3" rowspan="1">Tumour type (<italic toggle="yes">n</italic> = 107)</th></tr><tr><th align="center" rowspan="1" colspan="1">Sebaceoma</th><th align="center" rowspan="1" colspan="1">Adenoma</th><th align="center" rowspan="1" colspan="1">Carcinoma</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">MMRd</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Equivocal</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">MMRp</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>MMRd, mismatch repair deficient; MMRp, mismatch repair proficient; NA, not applicable due to uninterpretable technical artefacts.</p></fn></table-wrap-foot></table-wrap><p>The MMR proteins form two heterodimers, MutS&#x003b1; (composed of MSH2 and MSH6) and MutL&#x003b1; (composed of MLH1 and PMS2). MSH2 and MLH1 are essential for heterodimer stabilization, so loss of their expression leads to concurrent loss of MSH6 or PMS2 staining, respectively.<sup><xref rid="llaf005-B33" ref-type="bibr">33</xref>,<xref rid="llaf005-B34" ref-type="bibr">34</xref></sup> Concurrent loss of MSH2 and MSH6 expression was observed in the majority [<italic toggle="yes">n</italic> = 27/49 (55%), 95% CI 40&#x02013;69] of MMR-deficient STs. Isolated loss of MSH6 and of PMS2 expression can be seen as MSH2 and MLH1 can be stabilized by alternate heterodimers.<sup><xref rid="llaf005-B33" ref-type="bibr">33</xref>,<xref rid="llaf005-B34" ref-type="bibr">34</xref></sup> The isolated loss of MSH6 was observed in only 4 of the 49 cases (8%, 95% CI 2&#x02013;20), one of which also had equivocal staining for MSH2.</p><p>The interpretation of MLH1 expression was complicated by punctate staining patterns of varying intensity. Across 16 cases of potential MLH1 loss, 10 were considered to have equivocal MLH1 staining because of a strong punctate pattern, while the other 6 were considered to have loss of MLH1 expression with weak-to-medium punctate staining (Figure <xref rid="llaf005-F1" ref-type="fig">1</xref>). Interpretation was supported by analysis of PMS2 expression: 15 of the 16 STs with equivocal or absent MLH1 staining showed a clear absence of or weak PMS2 staining, suggesting loss of MLH1 expression. The other ST, a carcinoma with strong punctate (equivocal) MLH1 staining, showed equivocal PMS2 staining. Assuming strong punctate MLH1 staining with loss of PMS2 staining indicates loss of MLH1 expression,<sup><xref rid="llaf005-B35" ref-type="bibr">35&#x02013;38</xref></sup> concurrent loss of MLH1 and PMS2 expression was observed in 15/49 MMR-deficient ST (31%, 95% CI 18&#x02013;45), while isolated PMS2 expression loss was observed in only 1/49 (2%, 95% CI 0.1&#x02013;11%). Less common patterns of MMR expression loss were found in the remaining two MMR-deficient STs (4%; 95% CI 0.5&#x02013;14%), including absent staining of three or all four MMR proteins. There was no association between the pattern of expression loss and tumour subtype (<italic toggle="yes">P</italic> = 0.50), patient age (<italic toggle="yes">P</italic> = 0.94) or sex (<italic toggle="yes">P</italic> = 0.56).</p><fig position="float" id="llaf005-F1" fig-type="figure"><label>Figure 1</label><caption><p>Examples of variable immunohistochemistry (IHC) staining patterns of MLH1 from four sebaceous tumours ranging from retained MLH1 staining to weak punctate staining (middle panels). Haematoxylin and eosin staining (H&#x00026;E; left panels) and PMS2 IHC (right panels) are also shown for each tumour. Images were captured with a Nikon DS-Fi1-U2 at &#x000d7; 400 magnification. The red scale bar (top left panel) represents 50&#x02005;&#x003bc;m.</p></caption><graphic xlink:href="llaf005f1" position="float"/></fig></sec><sec id="llaf005-s2.3"><title>Microsatellite instability analysis is a sensitive and specific biomarker of mismatch repair deficiency in sebaceous tumours</title><p>All 107 STs were analysed by the Newcastle MSI-Plus assay. Forty-two STs were MSI-H (39.3%, 95% CI 30.0&#x02013;49.2) and 64 were MSS (59.8%, 95% CI 49.9&#x02013;69.2). One sample had an inconclusive classification (MSI score set to 0 after conflicting scores between &#x02013;5 and +5) (0.9%, 95% CI 0.0&#x02013;5.1). To estimate sensitivity and specificity of MSI analysis, MSI classification was compared with the IHC reference results for the 100 STs that had conclusive MSI and IHC classifications. MSI analysis achieved 83% sensitivity (95% CI 70&#x02013;93) by classification of 40/48 STs with loss of MMR expression as MSI-H, with 100% specificity (95% CI 93&#x02013;100%) by classification of 52/52 STs with retained MMR expression as MSS (Table <xref rid="llaf005-T2" ref-type="table">2</xref>). Of the eight STs with an MSS result discordant with the IHC reference, half had equivocal MLH1 staining with concurrent PMS2 loss, making this staining pattern over-represented among discordant cases (odds ratio 16.3; <italic toggle="yes">P</italic> = 1.89 &#x000d7; 10<sup>&#x02013;3</sup>).</p><table-wrap position="float" id="llaf005-T2"><label>Table 2</label><caption><p>Mismatch repair protein immunohistochemistry (IHC) staining pattern compared with microsatellite instability (MSI) classification by the Newcastle MSI-Plus assay in sebaceous tumours</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">IHC classification and staining pattern</th><th align="center" colspan="3" rowspan="1">MSI classification (<italic toggle="yes">n</italic> = 107)</th></tr><tr><th align="center" rowspan="1" colspan="1">MSS</th><th align="center" rowspan="1" colspan="1">Uncertain</th><th align="center" rowspan="1" colspan="1">MSI&#x02013;H</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">MMRd</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">MSH2/MSH6/MLH1/PMS2 loss</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MSH2/MSH6/PMS2 loss</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MSH2/MSH6 loss</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MSH2 eq., MSH6 loss</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MSH6 loss</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MLH1/PMS2 loss</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MLH1 eq., PMS2 loss</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;PMS2 loss</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Equivocal</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;MLH1/PMS2 eq.</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;PMS2 eq.</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">MMRp</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Retained</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Uninterpretable</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>eq., equivocal; MMRd, mismatch repair deficient; MMRp, mismatch repair proficient; MSI-H, microsatellite instability high; MSS, microsatellite stable; NA, not applicable due to uninterpretable technical artefacts.</p></fn></table-wrap-foot></table-wrap><p>It was not possible to comprehensively resolve discordance between the MMR deficiency tests, but reasons for discordance, as well as the origins of equivocal staining, were explored using MMR gene sequencing. Four of six MMR-deficient control STs had one or more pathogenic variants (PVs) detected, with each being concordant with the pattern of MMR IHC staining. Four of the eight STs with discordant results had a PV detected matching the pattern of MMR expression loss, suggesting that at least some of these were MMR deficient and were misclassified by MSI analysis. These included two MSH6-deficient STs and one ST with concurrent loss of expression of MSH2 and MSH6. Only one of the four STs with equivocal (strong punctate) MLH1 staining, loss of PMS2 and discordant MSS classification had an MMR PV detected, an <italic toggle="yes">MLH1</italic> splice site variant c.790 + 1G &#x0003e; A (Appendix <xref rid="sup1" ref-type="supplementary-material">S2</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supporting Information</xref>).</p><p>ST MSI scores were further compared with the patterns of MMR protein expression (Figure <xref rid="llaf005-F2" ref-type="fig">2</xref>). Three of the four MSH6-deficient STs were classified as MSS or had an inconclusive MSI score, and STs with concurrent loss of MSH2 and MSH6 had more positive MSI scores [median (range) +19.0 (&#x02013;22.4 to +30.7)] than STs with isolated MSH6 loss [median &#x02013;0.4 (&#x02013;7.6 to +19.3); <italic toggle="yes">P</italic> = 0. 03]. A similar comparison was not made for the MutL&#x003b1; proteins given the complexities of MLH1 staining interpretation and the single case with isolated PMS2 loss. There was a trend for MSI scores closer to 0 among the MSS STs that had lost MMR expression [median &#x02013;11.4 (&#x02013;23.1 to &#x02013;0.7)] compared with MSS STs that had retained MMR expression [median &#x02013;21.8 (&#x02013;23.5 to &#x02013;13.1); <italic toggle="yes">P</italic> = 0.06], suggesting MSI classification could be improved using a different score threshold. Indeed, the MSI classifier was trained on data from CRCs and MSI is known to have a weaker signal in nongastrointestinal tumours.<sup><xref rid="llaf005-B39" ref-type="bibr">39</xref></sup> The ROCauc provides a less biased estimate of diagnostic accuracy. Here, MSI scoring achieved a very high ROCauc of 0.944 for the detection of unequivocal loss vs. retention of MMR protein expression.</p><fig position="float" id="llaf005-F2" fig-type="figure"><label>Figure 2</label><caption><p>Mismatch repair (MMR) protein immunohistochemistry (IHC) staining pattern compared with microsatellite instability (MSI) scores generated by the Newcastle MSI-Plus assay in sebaceous tumours (<italic toggle="yes">n</italic> = 107). eq., equivocal.</p></caption><graphic xlink:href="llaf005f2" position="float"/></fig></sec></sec><sec sec-type="discussion" id="llaf005-s3"><title>Discussion</title><p>Universal MMR deficiency testing of STs to identify patients for constitutional (germline) genetic testing has recently been called for by UK experts in partnership with the Lynch Syndrome UK patient group to harmonize screening practice with CRC and EC.<sup><xref rid="llaf005-B12" ref-type="bibr">12</xref></sup> Here, we assessed the viability of a novel testing strategy using MSI analysis and a low-cost, scalable assay &#x02013; the Newcastle MSI-Plus assay &#x02013; that is already in clinical practice for CRC testing in parts of England.<sup><xref rid="llaf005-B17" ref-type="bibr">17</xref></sup> Using IHC as the reference method, MSI scoring had a ROCauc of 0.944 and achieved 83% sensitivity and 100% specificity using a score threshold defined from CRCs. This suggests that MSI analysis is a viable adjunct or alternative MMR deficiency test to IHC for LS screening in STs, and warrants further study in clinical practice.</p><p>In this study, 49 of 104 STs (47.1%, 95% CI 37.3&#x02013;57.2) were MMR deficient according to IHC, which falls in the middle of the broad range of 30&#x02013;66% reported in the literature from similar large-scale studies of consecutive patients with ST.<sup><xref rid="llaf005-B40" ref-type="bibr">40</xref>,<xref rid="llaf005-B41" ref-type="bibr">41</xref></sup> This broad range may reflect distinct IHC methodology and populations. The largest of these cohorts found an association between MMR deficiency and ST type, with increased frequency among adenoma and decreased frequency among sebaceoma and carcinoma.<sup><xref rid="llaf005-B41" ref-type="bibr">41</xref></sup> In contrast, we found adenoma and sebaceoma had comparable frequencies of MMR deficiency at 54% and 44%, respectively, but, in agreement, found carcinoma had the lowest frequency at 23%. Among MMR-deficient STs, the frequencies of IHC staining patterns are very similar between studies, with the majority having concurrent loss of MSH2 and MSH6 expression.<sup><xref rid="llaf005-B40" ref-type="bibr">40</xref>,<xref rid="llaf005-B41" ref-type="bibr">41</xref></sup></p><p>MMR IHC staining of STs returned an ambiguous result in approximately 10% of the cases we studied. Punctate nuclear staining of MLH1 is a known staining pattern associated with the MLH1 M1 antibody used in this study,<sup><xref rid="llaf005-B35" ref-type="bibr">35&#x02013;38</xref></sup> affecting as many as around 75% of tumours in other studies with the (potential) loss of MLH1 expression.<sup><xref rid="llaf005-B42" ref-type="bibr">42</xref></sup> In our study, punctate MLH1 staining was seen in each of the 16 STs with the (potential) MLH1 expression loss. Strong punctate staining presents a challenge to interpretation with a risk of erroneous classification as retained expression. A pragmatic approach is to regard any punctate MLH1 staining as defective/equivocal where there is supportive loss of PMS2 staining. However, this potentially reduces testing specificity, supported by the reduced concordance with MSI testing observed in these cases. The available material limited our ability to identify possible reasons for discordance (Appendix <xref rid="sup1" ref-type="supplementary-material">S2</xref>) and the MMR gene sequencing method used has limitations, in particular being insensitive to epigenetic variants, such as <italic toggle="yes">MLH1</italic> promoter methylation, that often disrupt MMR function.<sup><xref rid="llaf005-B43" ref-type="bibr">43</xref>,<xref rid="llaf005-B44" ref-type="bibr">44</xref></sup> Therefore, the association between strong punctate MLH1 staining with PMS2 loss and discordant MSS classification remains unexplained. However, sequencing identified <italic toggle="yes">MLH1</italic> c.790+1G&#x0003e;A in one such ST and, interestingly, <italic toggle="yes">MLH1</italic> c.790+1G&#x0003e;A is a splice site variant that causes in-frame skipping of <italic toggle="yes">MLH1</italic> exons 9 and 10 and, therefore, a shortened protein that may retain antigenicity.<sup><xref rid="llaf005-B45" ref-type="bibr">45</xref></sup></p><p>Reduced MSI has been observed in MSH6-deficient tumours, even when exclusively analysing mononucleotide repeats (given MSH6 has no role in the repair of longer motif microsatellites such as di- or trinucleotide repeats), including CRC<sup><xref rid="llaf005-B46" ref-type="bibr">46</xref></sup> and EC.<sup><xref rid="llaf005-B47" ref-type="bibr">47</xref></sup> This is also seen in MSH6-deficient blood from patients with constitutional MMR deficiency,<sup><xref rid="llaf005-B20" ref-type="bibr">20</xref>,<xref rid="llaf005-B48" ref-type="bibr">48</xref></sup> and is likely due to redundancy in repair between MutS&#x003b1; (MSH2&#x02013;MSH6) and MutS&#x003b2; (MSH2&#x02013;MSH3) heterodimers.<sup><xref rid="llaf005-B33" ref-type="bibr">33</xref>,<xref rid="llaf005-B34" ref-type="bibr">34</xref></sup> Three of four STs with isolated MSH6 deficiency had discordant MSS or uncertain classification and STs with isolated MSH6 loss had significantly lower MSI scores than STs with concurrent MSH2 and MSH6 loss, therefore showing the association of reduced MSI and MSH6 deficiency holds for ST.</p><p>In conclusion, MSI analysis is an effective MMR-deficiency test in ST and may reduce false-positive IHC results. In addition, MSI analysis can detect MMR deficiency where MMR protein expression is retained,<sup><xref rid="llaf005-B15" ref-type="bibr">15</xref>,<xref rid="llaf005-B16" ref-type="bibr">16</xref></sup> although no such cases were identified in this study. Therefore, MSI assays may be used as adjunct or alternative MMR deficiency tests to IHC in ST, which would facilitate low-cost and integrated LS screening programmes in this currently overlooked tumour type.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data"><label>llaf005_Supplementary_Data</label><media xlink:href="llaf005_supplementary_data.zip"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>We are grateful to NovoPath, The Newcastle upon Tyne Hospitals NHS Foundation Trust, staff members Tom Ness and Rowen Coulthard for technical support during tissue sectioning and staining, the Northern Genetics Service, The Newcastle upon Tyne Hospitals NHS Foundation Trust, for provision of multiplex polymerase chain reaction primer pools, and the Genomics Core Facility, Newcastle University, for MiSeq access.</p></ack><sec id="llaf005-s4"><title>Funding sources</title><p>This work was supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), North Eastern Skin Research Fund, Cancer Research UK and the Kuwait Ministry of Health. N.R. research is supported by the NIHR Newcastle BRC.</p></sec><sec sec-type="data-availability" id="llaf005-s6"><title>Data availability</title><p>FASTQ files generated by the Newcastle MSI-Plus assay and MMR gene MIP amplicon sequencing are available from the European Nucleotide Archive (<ext-link xlink:href="https://www.ebi.ac.uk/ena/browser/home" ext-link-type="uri">https://www.ebi.ac.uk/ena/browser/home</ext-link>) using study IDs PRJEB79222 and PRJEB79223, respectively.</p></sec><sec id="llaf005-s7"><title>Ethics statement</title><p>Ethical approval of the study was granted by the NHS Health Research Authority (REC references: 13/LO/1514 and 17/NE/0070).</p></sec><sec id="llaf005-s8"><title>Patient consent</title><p>Not applicable.</p></sec><sec id="llaf005-s9"><title>Supporting Information</title><p>Additional <xref rid="sup1" ref-type="supplementary-material">Supporting Information</xref> may be found in the online version of this article at the publisher&#x02019;s website.</p></sec><ref-list id="ref1"><title>References</title><ref id="llaf005-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ferreira</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Wiedemeyer</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Demetter</surname> &#x000a0;<given-names>P</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Update on the pathology, genetics and somatic landscape of sebaceous tumours</article-title>. <source>Histopathology</source> &#x000a0;<year>2020</year>; <volume>76</volume>:<fpage>640</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31821583</pub-id>
</mixed-citation></ref><ref id="llaf005-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schon</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Rytina</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Drummond</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting</article-title>. <source>Clin Exp Dermatol</source> &#x000a0;<year>2018</year>; <volume>43</volume>:<fpage>410</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">29333623</pub-id>
</mixed-citation></ref><ref id="llaf005-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cook</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Pethick</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Kibbi</surname> &#x000a0;<given-names>N</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018</article-title>. <source>J Am Acad Dermatol</source> &#x000a0;<year>2023</year>; <volume>89</volume>:<fpage>1129</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">37031776</pub-id>
</mixed-citation></ref><ref id="llaf005-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crosbie</surname> &#x000a0;<given-names>EJ</given-names></string-name>, <string-name><surname>Ryan</surname> &#x000a0;<given-names>NAJ</given-names></string-name>, <string-name><surname>Arends</surname> &#x000a0;<given-names>MJ</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome</article-title>. <source>Genet Med</source> &#x000a0;<year>2019</year>; <volume>21</volume>:<fpage>2390</fpage>&#x02013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">30918358</pub-id>
</mixed-citation></ref><ref id="llaf005-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sepp&#x000e4;l&#x000e4;</surname> &#x000a0;<given-names>TT</given-names></string-name>, <string-name><surname>Latchford</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Negoi</surname> &#x000a0;<given-names>I</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender</article-title>. <source>Br J Surg</source> &#x000a0;<year>2021</year>; <volume>108</volume>:<fpage>484</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">34043773</pub-id>
</mixed-citation></ref><ref id="llaf005-B6"><label>6</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>UK National Institute for Health and Care Excellence</collab>
</person-group>. Molecular testing strategies for Lynch syndrome in people with colorectal cancer [Diagnostics Guidance 27]. Available at: <ext-link xlink:href="https://www.nice.org.uk/guidance/dg27" ext-link-type="uri">https://www.nice.org.uk/guidance/dg27</ext-link> (last accessed 2 October 2024).</mixed-citation></ref><ref id="llaf005-B7"><label>7</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>UK National Institute for Health and Care Excellence</collab>
</person-group>. Testing strategies for Lynch syndrome in people with endometrial cancer [Diagnostics Guidance 42]. Available at: <ext-link xlink:href="https://www.nice.org.uk/guidance/dg42" ext-link-type="uri">https://www.nice.org.uk/guidance/dg42</ext-link> (last accessed 2 October 2024).</mixed-citation></ref><ref id="llaf005-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Aziz</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>O&#x02019;Sullivan</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Heelan</surname> &#x000a0;<given-names>K</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review</article-title>. <source>Fam Cancer</source> &#x000a0;<year>2023</year>; <volume>22</volume>:<fpage>167</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">36418753</pub-id>
</mixed-citation></ref><ref id="llaf005-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roberts</surname> &#x000a0;<given-names>ME</given-names></string-name>, <string-name><surname>Riegert-Johnson</surname> &#x000a0;<given-names>DL</given-names></string-name>, <string-name><surname>Thomas</surname> &#x000a0;<given-names>BC</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome</article-title>. <source>Genet Med</source> &#x000a0;<year>2014</year>; <volume>16</volume>:<fpage>711</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">24603434</pub-id>
</mixed-citation></ref><ref id="llaf005-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Everett</surname> &#x000a0;<given-names>JN</given-names></string-name>, <string-name><surname>Raymond</surname> &#x000a0;<given-names>VM</given-names></string-name>, <string-name><surname>Dandapani</surname> &#x000a0;<given-names>M</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm</article-title>. <source>JAMA Dermatol</source> &#x000a0;<year>2014</year>; <volume>150</volume>:<fpage>1315</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">25006859</pub-id>
</mixed-citation></ref><ref id="llaf005-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Owen</surname> &#x000a0;<given-names>JL</given-names></string-name>, <string-name><surname>Kibbi</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Worley</surname> &#x000a0;<given-names>B</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Sebaceous carcinoma: &#x000ad;evidence-based clinical practice guidelines</article-title>. <source>Lancet Oncol</source> &#x000a0;<year>2019</year>; <volume>20</volume>:<fpage>e699</fpage>&#x02013;<lpage>714</lpage>.<pub-id pub-id-type="pmid">31797796</pub-id>
</mixed-citation></ref><ref id="llaf005-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rajan</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Cook</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Best</surname> &#x000a0;<given-names>K</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Universal testing of cutaneous sebaceous carcinoma: a missed opportunity in Lynch syndrome detection</article-title>. <source>Lancet Oncol</source> &#x000a0;<year>2024</year>; <volume>25</volume>:<fpage>e1</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">38181808</pub-id>
</mixed-citation></ref><ref id="llaf005-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Le</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>Durham</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Smith</surname> &#x000a0;<given-names>K</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title>. <source>Science</source> &#x000a0;<year>2017</year>; <volume>357</volume>:<fpage>409</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">28596308</pub-id>
</mixed-citation></ref><ref id="llaf005-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Burn</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Sheth</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Elliott</surname> &#x000a0;<given-names>F</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year &#x000ad;follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</article-title>. <source>Lancet</source> &#x000a0;<year>2020</year>; <volume>395</volume>:<fpage>1855</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">32534647</pub-id>
</mixed-citation></ref><ref id="llaf005-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname> &#x000a0;<given-names>W</given-names></string-name>, <string-name><surname>Hampel</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Pearlman</surname> &#x000a0;<given-names>R</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome</article-title>. <source>Hum Pathol</source> &#x000a0;<year>2020</year>; <volume>103</volume>:<fpage>34</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">32652087</pub-id>
</mixed-citation></ref><ref id="llaf005-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hechtman</surname> &#x000a0;<given-names>JF</given-names></string-name>, <string-name><surname>Rana</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Middha</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes</article-title>. <source>Mod Pathol</source> &#x000a0;<year>2020</year>; <volume>33</volume>:<fpage>871</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31857677</pub-id>
</mixed-citation></ref><ref id="llaf005-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gallon</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Herrero-Belmonte</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Phelps</surname> &#x000a0;<given-names>R</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>A novel colorectal cancer test combining microsatellite instability and BRAF/RAS analysis: clinical validation and impact on Lynch syndrome screening</article-title>. <source>BJC Rep</source> &#x000a0;<year>2024</year>; <volume>2</volume>:<fpage>48</fpage>.<pub-id pub-id-type="pmid">38962168</pub-id>
</mixed-citation></ref><ref id="llaf005-B18"><label>18</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Elder</surname> &#x000a0;<given-names>DE</given-names></string-name>, <string-name><surname>Massi</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>Scolyer</surname> &#x000a0;<given-names>RA</given-names></string-name>, <string-name><surname>Willemze</surname> &#x000a0;<given-names>R</given-names></string-name></person-group>. <part-title>WHO classification of skin tumours</part-title>. In: <source>WHO Classification of Tumours</source> (<person-group person-group-type="editor"><string-name><surname>Elder</surname> &#x000a0;<given-names>DE</given-names></string-name>, <string-name><surname>Massi</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>Scolyer</surname> &#x000a0;<given-names>RA</given-names></string-name>, <string-name><surname>Willemze</surname> &#x000a0;<given-names>R</given-names></string-name></person-group>, eds), <edition>4th edn</edition>. <publisher-name>IARC Publications</publisher-name>, <year>2018</year>.</mixed-citation></ref><ref id="llaf005-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Redford</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Alhilal</surname> &#x000a0;<given-names>G</given-names></string-name>, <string-name><surname>Needham</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>A novel panel of short mononucleotide repeats linked to informative polymorphisms enabling effective high volume low cost discrimination between mismatch repair deficient and proficient tumours</article-title>. <source>PLoS One</source> &#x000a0;<year>2018</year>; <volume>13</volume>:<fpage>e0203052</fpage>.<pub-id pub-id-type="pmid">30157243</pub-id>
</mixed-citation></ref><ref id="llaf005-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gallon</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Phelps</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Hayes</surname> &#x000a0;<given-names>C</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Constitutional microsatellite instability, genotype, and phenotype correlations in constitutional mismatch repair deficiency</article-title>. <source>Gastroenterology</source> &#x000a0;<year>2023</year>; <volume>164</volume>:<fpage>579</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">36586540</pub-id>
</mixed-citation></ref><ref id="llaf005-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Durbin</surname> &#x000a0;<given-names>R</given-names></string-name></person-group>. <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source> &#x000a0;<year>2009</year>; <volume>25</volume>:<fpage>1754</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id>
</mixed-citation></ref><ref id="llaf005-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hiatt</surname> &#x000a0;<given-names>JB</given-names></string-name>, <string-name><surname>Pritchard</surname> &#x000a0;<given-names>CC</given-names></string-name>, <string-name><surname>Salipante</surname> &#x000a0;<given-names>SJ</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation</article-title>. <source>Genome Res</source> &#x000a0;<year>2013</year>; <volume>23</volume>:<fpage>843</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">23382536</pub-id>
</mixed-citation></ref><ref id="llaf005-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boyle</surname> &#x000a0;<given-names>EA</given-names></string-name>, <string-name><surname>O&#x02019;Roak</surname> &#x000a0;<given-names>BJ</given-names></string-name>, <string-name><surname>Martin</surname> &#x000a0;<given-names>BK</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>MIPgen: optimized modeling and design of molecular inversion probes for targeted resequencing</article-title>. <source>Bioinformatics</source> &#x000a0;<year>2014</year>; <volume>30</volume>:<fpage>2670</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">24867941</pub-id>
</mixed-citation></ref><ref id="llaf005-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gallon</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Sheth</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Hayes</surname> &#x000a0;<given-names>C</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Sequencing-based microsatellite instability testing using as few as six markers for high-throughput clinical diagnostics</article-title>. <source>Hum Mutat</source> &#x000a0;<year>2020</year>; <volume>41</volume>:<fpage>332</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">31471937</pub-id>
</mixed-citation></ref><ref id="llaf005-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Handsaker</surname> &#x000a0;<given-names>B</given-names></string-name>, <string-name><surname>Wysoker</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>The Sequence Alignment/Map format and SAMtools</article-title>. <source>Bioinformatics</source> &#x000a0;<year>2009</year>; <volume>25</volume>:<fpage>2078</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19505943</pub-id>
</mixed-citation></ref><ref id="llaf005-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Au</surname> &#x000a0;<given-names>CH</given-names></string-name>, <string-name><surname>Ho</surname> &#x000a0;<given-names>DN</given-names></string-name>, <string-name><surname>Kwong</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>BAMClipper: removing primers from alignments to minimize false-negative mutations in amplicon next-generation sequencing</article-title>. <source>Sci Rep</source> &#x000a0;<year>2017</year>; <volume>7</volume>:<year>1567</year>.</mixed-citation></ref><ref id="llaf005-B27"><label>27</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Van der Auwera</surname> &#x000a0;<given-names>GA</given-names></string-name>, <string-name><surname>O&#x02019;Connor</surname> &#x000a0;<given-names>B</given-names></string-name></person-group>. <source>Genomics in the Cloud</source>. <publisher-name>O&#x02019;Reilly Media, Inc.</publisher-name>, <year>2020</year>.</mixed-citation></ref><ref id="llaf005-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McLaren</surname> &#x000a0;<given-names>W</given-names></string-name>, <string-name><surname>Gil</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Hunt</surname> &#x000a0;<given-names>SE</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>The Ensembl variant effect predictor</article-title>. <source>Genome Biol</source> &#x000a0;<year>2016</year>; <volume>17</volume>:<fpage>122</fpage>.<pub-id pub-id-type="pmid">27268795</pub-id>
</mixed-citation></ref><ref id="llaf005-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Knaus</surname> &#x000a0;<given-names>BJ</given-names></string-name>
</person-group>, <article-title>Gr&#x000fc;nwald NJ. vcfr: a package to manipulate and visualize variant call format data in R</article-title>. <source>Mol Ecol Resour</source> &#x000a0;<year>2017</year>; <volume>17</volume>:<fpage>44</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">27401132</pub-id>
</mixed-citation></ref><ref id="llaf005-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Landrum</surname> &#x000a0;<given-names>MJ</given-names></string-name>, <string-name><surname>Lee</surname> &#x000a0;<given-names>JM</given-names></string-name>, <string-name><surname>Riley</surname> &#x000a0;<given-names>GR</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>ClinVar: public archive of relationships among sequence variation and human phenotype</article-title>. <source>Nucleic Acids Res</source> &#x000a0;<year>2014</year>; <volume>42</volume>:<fpage>D980</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">24234437</pub-id>
</mixed-citation></ref><ref id="llaf005-B31"><label>31</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Wickham</surname> &#x000a0;<given-names>H</given-names></string-name>
</person-group>. <source>ggplot2: Elegant Graphics for Data Analysis</source>. <publisher-name>Springer</publisher-name>, <year>2016</year>.</mixed-citation></ref><ref id="llaf005-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Robin</surname> &#x000a0;<given-names>X</given-names></string-name>, <string-name><surname>Turck</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Hainard</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title>. <source>BMC Bioinformatics</source> &#x000a0;<year>2011</year>; <volume>12</volume>:<issue>77</issue>.</mixed-citation></ref><ref id="llaf005-B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kunkel</surname> &#x000a0;<given-names>T</given-names></string-name>, <string-name><surname>Erie</surname> &#x000a0;<given-names>D</given-names></string-name></person-group>. <article-title>DNA mismatch repair</article-title>. <source>Annu Rev Biochem</source> &#x000a0;<year>2005</year>; <volume>74</volume>:<fpage>681</fpage>&#x02013;<lpage>710</lpage>.<pub-id pub-id-type="pmid">15952900</pub-id>
</mixed-citation></ref><ref id="llaf005-B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jiricny</surname> &#x000a0;<given-names>J</given-names></string-name>
</person-group>. <article-title>The multifaceted mismatch-repair system</article-title>. <source>Nat Rev Mol Cell Biol</source> &#x000a0;<year>2006</year>; <volume>7</volume>:<fpage>335</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">16612326</pub-id>
</mixed-citation></ref><ref id="llaf005-B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Niu</surname> &#x000a0;<given-names>BT</given-names></string-name>, <string-name><surname>Hammond</surname> &#x000a0;<given-names>RFL</given-names></string-name>, <string-name><surname>Leen</surname> &#x000a0;<given-names>SLS</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss</article-title>. <source>Histopathology</source> &#x000a0;<year>2018</year>; <volume>73</volume>:<fpage>703</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">29852531</pub-id>
</mixed-citation></ref><ref id="llaf005-B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Loughrey</surname> &#x000a0;<given-names>MB</given-names></string-name>, <string-name><surname>Dunne</surname> &#x000a0;<given-names>PD</given-names></string-name>, <string-name><surname>Coleman</surname> &#x000a0;<given-names>HG</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Punctate MLH1 mismatch repair immunostaining in colorectal cancer</article-title>. <source>Histopathology</source> &#x000a0;<year>2019</year>; <volume>74</volume>:<fpage>795</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30379344</pub-id>
</mixed-citation></ref><ref id="llaf005-B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dasgupta</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Ewing-Graham</surname> &#x000a0;<given-names>PC</given-names></string-name>, <string-name><surname>Groenendijk</surname> &#x000a0;<given-names>FH</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Granular dot-like staining with MLH1 immunohistochemistry is a clone-&#x000ad;dependent artefact</article-title>. <source>Pathol Res Pract</source> &#x000a0;<year>2020</year>; <volume>216</volume>:<fpage>152581</fpage>.<pub-id pub-id-type="pmid">31402167</pub-id>
</mixed-citation></ref><ref id="llaf005-B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname> &#x000a0;<given-names>Q</given-names></string-name>, <string-name><surname>Young</surname> &#x000a0;<given-names>GQ</given-names></string-name>, <string-name><surname>Yang</surname> &#x000a0;<given-names>Z</given-names></string-name></person-group>. <article-title>Pure discrete punctate nuclear staining pattern for MLH1 protein does not represent intact nuclear expression</article-title>. <source>Int J Surg Pathol</source> &#x000a0;<year>2020</year>; <volume>28</volume>:<fpage>146</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">31566049</pub-id>
</mixed-citation></ref><ref id="llaf005-B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bartley</surname> &#x000a0;<given-names>AN</given-names></string-name>, <string-name><surname>Mills</surname> &#x000a0;<given-names>AM</given-names></string-name>, <string-name><surname>Konnick</surname> &#x000a0;<given-names>E</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer</article-title>. <source>Arch Pathol Lab Med</source> &#x000a0;<year>2022</year>; <volume>146</volume>:<fpage>1194</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">35920830</pub-id>
</mixed-citation></ref><ref id="llaf005-B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jessup</surname> &#x000a0;<given-names>CJ</given-names></string-name>, <string-name><surname>Redston</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Tilton</surname> &#x000a0;<given-names>E</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome</article-title>. <source>Hum Pathol</source> &#x000a0;<year>2016</year>; <volume>49</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26826402</pub-id>
</mixed-citation></ref><ref id="llaf005-B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walsh</surname> &#x000a0;<given-names>MD</given-names></string-name>, <string-name><surname>Jayasekara</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Huang</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: a large case series from a single Australian private pathology service</article-title>. <source>Australas J Dermatol</source> &#x000a0;<year>2019</year>; <volume>60</volume>:<fpage>126</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">30506759</pub-id>
</mixed-citation></ref><ref id="llaf005-B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yoshida</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Takigawa</surname> &#x000a0;<given-names>W</given-names></string-name>, <string-name><surname>Kobayashi-Kato</surname> &#x000a0;<given-names>M</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Mismatch repair protein expression in endometrial cancer: assessing concordance and unveiling pitfalls in two different immunohistochemistry assays</article-title>. <source>J Pers Med</source> &#x000a0;<year>2023</year>; <volume>13</volume>:<year>1260</year>.</mixed-citation></ref><ref id="llaf005-B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>P&#x000e9;rez-Carbonell</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Alenda</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Pay&#x000e1;</surname> &#x000a0;<given-names>A</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome</article-title>. <source>J Mol Diagn</source> &#x000a0;<year>2010</year>; <volume>12</volume>:<fpage>498</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">20489114</pub-id>
</mixed-citation></ref><ref id="llaf005-B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Metcalf</surname> &#x000a0;<given-names>AM</given-names></string-name>, <string-name><surname>Spurdle</surname> &#x000a0;<given-names>AB</given-names></string-name></person-group>. <article-title>Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review</article-title>. <source>Fam Cancer</source> &#x000a0;<year>2014</year>; <volume>13</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">23880961</pub-id>
</mixed-citation></ref><ref id="llaf005-B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Auclair</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Busine</surname> &#x000a0;<given-names>MP</given-names></string-name>, <string-name><surname>Navarro</surname> &#x000a0;<given-names>C</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing</article-title>. <source>Hum Mutat</source> &#x000a0;<year>2006</year>; <volume>27</volume>:<fpage>145</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">16395668</pub-id>
</mixed-citation></ref><ref id="llaf005-B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Helderman</surname> &#x000a0;<given-names>NC</given-names></string-name>, <string-name><surname>Van Der Werf-&#x02019;t Lam</surname> &#x000a0;<given-names>AS</given-names></string-name>, <string-name><surname>Morreau</surname> &#x000a0;<given-names>H</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>Molecular profile of MSH6-associated colorectal carcinomas shows distinct features from other Lynch syndrome-associated colorectal carcinomas</article-title>. <source>Gastroenterology</source> &#x000a0;<year>2023</year>; <volume>165</volume>:<fpage>271</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">36931573</pub-id>
</mixed-citation></ref><ref id="llaf005-B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ryan</surname> &#x000a0;<given-names>NAJ</given-names></string-name>, <string-name><surname>McMahon</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Tobi</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study</article-title>. <source>PLoS Med</source> &#x000a0;<year>2020</year>; <volume>17</volume>:<fpage>e1003263</fpage>.<pub-id pub-id-type="pmid">32941469</pub-id>
</mixed-citation></ref><ref id="llaf005-B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gonz&#x000e1;lez-Acosta</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Mar&#x000ed;n</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Puliafito</surname> &#x000a0;<given-names>B</given-names></string-name> &#x000a0;<etal>et al</etal></person-group> &#x000a0;<article-title>High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers</article-title>. <source>J Med Genet</source> &#x000a0;<year>2020</year>; <volume>57</volume>:<fpage>269</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">31494577</pub-id>
</mixed-citation></ref></ref-list></back></article>